Scarica l'app Stockscreener
2.305
5.53%
-0.135
Pre-mercato:
2.33
0.025
+1.08%
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Canada
Ovid Therapeutics (OVID) Edges Higher, Holding Above Key Support ZoneMoving Average Ribbon - dars.gov.et
FEDERATED HERMES, INC. Increases Stake in Ovid Therapeutics Inc - GuruFocus
Ovid Therapeutics names new chief business officer By Investing.com - Investing.com Nigeria
Ovid Therapeutics Appoints New Executives to Drive Strategic Growth - sekbernews.id
Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer - Yahoo Finance
Ovid Therapeutics appoints Charles Carter as new CFO - The Globe and Mail
Form 4 Ovid Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
Ovid Therapeutics (ticker: OVID) grants CFO 50,000 RSUs vesting 2027-2028 - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) CFO reports 44,375 shares and long-dated stock options - Stock Titan
Ovid Therapeutics Says Carter Has More Than 30 Yrs of Experience Across Finance, Strategy, Operational Leadership >OVID - Moomoo
PR News | On the Move: Ovid Therapeutics Hires Fort as CSOWed., Jul. 8, 2026 - O'Dwyer's PR
Ovid Therapeutics names new chief business officer - Investing.com
Ovid Therapeutics: Victoria Fort Promoted to Chief Strategy Officer >OVID - Moomoo
Federated Hermes (NASDAQ: OVID) holds 7.74M shares, 4.15% disclosed - Stock Titan
Ovid Therapeutics: Norrett Most Recently Served as Chief Business Officer at Soleno Therapeutics, Where He Led Company's Acquisition by Neurocrine Biosciences >OVID - Moomoo
Ovid Therapeutics names Charles Carter as CFO as Jeffrey Rona transitions from finance roles - TradingView
New Ovid Therapeutics (NASDAQ: OVID) CFO named as Rona transitions to consultant - Stock Titan
Ovid Therapeutics Strengthens Executive Leadership Team to - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally - Seeking Alpha
Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329, TSC/IS Expansions - Seeking Alpha
Ovid Therapeutics upgraded to Buy as OV329 shows strong safety and advances in epilepsy treatment trials. - Pluang
Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth - Sahm
Ovid Therapeutics Inc.(NasdaqCM:OVID) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2500 Growth Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Value Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM:OVID) added to Russell Microcap Value Benchmark Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Growth Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 3000E Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell Microcap Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 3000E Growth Benchmark - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2500 Index - marketscreener.com
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 3000E Value Benchmark - marketscreener.com
Ovid Therapeutics Inc (OVID) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ovid Therapeutics Inc. Actuals & Estimates (NASDAQ:OVID) - TradingView
OVID Forecast — Price Target — Prediction for 2027 - TradingView
AQST Stock Price and Chart — NASDAQ:AQST - TradingView
1OT Forecast — Price Target — Prediction for 2027 - TradingView
Ovid Therapeutics Inc. Actuals & Estimates (SWB:1OT) - TradingView
Price to book forward of Ovid Therapeutics Inc. – NASDAQ:OVID - TradingView
Price to earnings forward of Ovid Therapeutics Inc. – NASDAQ:OVID - TradingView
Price to sales forward of Ovid Therapeutics Inc. – NASDAQ:OVID - TradingView
Ovid Therapeutics Inc (OVID) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy - Sahm
Ovid Therapeutics Inc.(NasdaqCM: OVID) added to S&P Biotechnology Select Industry Index - marketscreener.com
Ovid Therapeutics (OVID) Shares Decline 6.2% as Stock Tests Support Near $2.16Mid Cap Momentum - DonanımHaber
OVIDOvid Therapeutics Inc Latest SEC Filings - Finviz
OVID Q1 2026 Earnings: Narrower-than-Expected Loss But Stock Declines 6.2%Annual Financial Report - dars.gov.et
Ovid Therapeutics (NASDAQ: OVID) grants director Anna Greka 130,000 stock options - Stock Titan
Ovid Therapeutics (OVID) director files initial Form 3 - Stock Titan
Ovid Therapeutics Inc (OVID) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ovid Therapeutics Inc (OVID) Institutional Confidence - TradingKey
Ovid Therapeutics Inc (OVID) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ovid Therapeutics Inc (OVID) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ovid Therapeutics Inc (OVID) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ovid Therapeutics Inc (OVID) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ovid Therapeutics Inc (OVID) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OVID: Multiple clinical milestones and strong financial runway position the pipeline for significant value creation - TradingView
0.74%
3.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):